Tags

Type your tag names separated by a space and hit enter

Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
Vaccine. 2008 Mar 25; 26(14):1742-50.V

Abstract

Avian-to-human transmission of the high pathogenicity (HP) H7N7 subtype avian influenza viruses in the Netherlands during 2003 caused zoonotic infections in 89 people, including a case of acute fatal respiratory distress syndrome. Public health emergency preparedness against H7N7 avian influenza viruses with pandemic potential includes the development of vaccine candidate viruses. In order to develop a high growth reassortant vaccine candidate virus, low pathogenicity (LP) A/mallard/Netherlands/12/2000 (H7N3) and A/mallard/Netherlands/2/2000 (H10N7) strains were selected as donors of the H7 haemagglutinin and N7 neuraminidase genes, respectively. The donor viruses exhibited high amino acid sequence homology with the surface glycoproteins of A/Netherlands/219/03 H7N7 virus (NL219), an isolate recovered from the fatal human case. Adhering to the seasonal influenza vaccine licensure regulations, we generated a H7N7/PR8 reassortant containing desired surface glycoprotein genes from the mallard viruses and internal genes of A/Puerto Rico/8/34 human vaccine strain (H1N1). Antigenic analysis revealed that the vaccine candidate virus confers broad antigenic cross-reactivity against contemporary Eurasian and the North American H7 subtype human isolates. Mice immunized with formalin inactivated (FI) H7N7/PR8 whole virus vaccine with or without aluminum hydroxide adjuvant conferred clinical protection from mortality and reduced pulmonary replication of the NL219 challenge virus. The FI H7N7/PR8 whole virus vaccine also afforded cross-protection in mice at the pulmonary level against antigenically distinct North American LP A/Canada/444/04 (H7N3) human isolate. The vaccine candidate virus satisfied the agricultural safety requirements for chickens, proved safe in mice, and has entered in phase-I human clinical trial in the United States.

Authors+Show Affiliations

Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, GA 30333, USA. Samadhan.Jadhao@ars.usda.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

18336962

Citation

Jadhao, Samadhan J., et al. "Development of Eurasian H7N7/PR8 High Growth Reassortant Virus for Clinical Evaluation as an Inactivated Pandemic Influenza Vaccine." Vaccine, vol. 26, no. 14, 2008, pp. 1742-50.
Jadhao SJ, Achenbach J, Swayne DE, et al. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine. 2008;26(14):1742-50.
Jadhao, S. J., Achenbach, J., Swayne, D. E., Donis, R., Cox, N., & Matsuoka, Y. (2008). Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine, 26(14), 1742-50. https://doi.org/10.1016/j.vaccine.2008.01.036
Jadhao SJ, et al. Development of Eurasian H7N7/PR8 High Growth Reassortant Virus for Clinical Evaluation as an Inactivated Pandemic Influenza Vaccine. Vaccine. 2008 Mar 25;26(14):1742-50. PubMed PMID: 18336962.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. AU - Jadhao,Samadhan J, AU - Achenbach,Jenna, AU - Swayne,David E, AU - Donis,Ruben, AU - Cox,Nancy, AU - Matsuoka,Yumiko, Y1 - 2008/02/13/ PY - 2007/11/09/received PY - 2008/01/11/revised PY - 2008/01/14/accepted PY - 2008/3/14/pubmed PY - 2008/5/29/medline PY - 2008/3/14/entrez SP - 1742 EP - 50 JF - Vaccine JO - Vaccine VL - 26 IS - 14 N2 - Avian-to-human transmission of the high pathogenicity (HP) H7N7 subtype avian influenza viruses in the Netherlands during 2003 caused zoonotic infections in 89 people, including a case of acute fatal respiratory distress syndrome. Public health emergency preparedness against H7N7 avian influenza viruses with pandemic potential includes the development of vaccine candidate viruses. In order to develop a high growth reassortant vaccine candidate virus, low pathogenicity (LP) A/mallard/Netherlands/12/2000 (H7N3) and A/mallard/Netherlands/2/2000 (H10N7) strains were selected as donors of the H7 haemagglutinin and N7 neuraminidase genes, respectively. The donor viruses exhibited high amino acid sequence homology with the surface glycoproteins of A/Netherlands/219/03 H7N7 virus (NL219), an isolate recovered from the fatal human case. Adhering to the seasonal influenza vaccine licensure regulations, we generated a H7N7/PR8 reassortant containing desired surface glycoprotein genes from the mallard viruses and internal genes of A/Puerto Rico/8/34 human vaccine strain (H1N1). Antigenic analysis revealed that the vaccine candidate virus confers broad antigenic cross-reactivity against contemporary Eurasian and the North American H7 subtype human isolates. Mice immunized with formalin inactivated (FI) H7N7/PR8 whole virus vaccine with or without aluminum hydroxide adjuvant conferred clinical protection from mortality and reduced pulmonary replication of the NL219 challenge virus. The FI H7N7/PR8 whole virus vaccine also afforded cross-protection in mice at the pulmonary level against antigenically distinct North American LP A/Canada/444/04 (H7N3) human isolate. The vaccine candidate virus satisfied the agricultural safety requirements for chickens, proved safe in mice, and has entered in phase-I human clinical trial in the United States. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/18336962/Development_of_Eurasian_H7N7/PR8_high_growth_reassortant_virus_for_clinical_evaluation_as_an_inactivated_pandemic_influenza_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(08)00082-0 DB - PRIME DP - Unbound Medicine ER -